Preclinical models of infectious diseases
Ended Awarded Last action
- Contract number
- 75N93022F00002
- Awardee
-
Utah State University UEI SPE2YDWHDYU4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,002,255
Award facts
- Contract value 65% obligated
-
- $1,002,255.00 Current, with exercised options
- $1,530,720.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Logan, UT 84322, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$17,550 | |
| Exercise an Option | $192,750 | |
| Exercise an Option | $192,750 | |
| Exercise an Option | $209,550 | |
| Original award | $424,755 |
About this award
Utah State University was awarded a $1.53M delivery order under the National Institute of Allergy and Infectious Diseases (NIAID) Preclinical Models of Infectious Diseases indefinite delivery/indefinite quantity (IDIQ) contract, with an ultimate completion date of July 17, 2025. This firm fixed-price delivery order, issued on July 18, 2022, supports the FY 2026 UDO Initiative and includes a de-obligation of excess funds. The work will be performed in Logan, Utah. The parent IDIQ contract, valued at $146.3M through July 2031, represents NIAID's largest single-award indefinite delivery vehicle with USU and funds the development and evaluation of animal models—including small animal, non-human primate, and alternative models—to test countermeasures such as vaccines, therapeutics, and diagnostics against priority infectious agents including pandemic RNA viruses, antimicrobial-resistant infections, and neglected tropical diseases.
As a 1862 land-grant public research institution, USU is a substantial federal contractor with demonstrated expertise in specialized infectious disease research and biodefense applications. The university's infectious disease research capabilities encompass the generation and distribution of specialized reagents supporting infectious disease research, positioning USU as a critical partner in national public health preparedness and biodefense initiatives. No set-aside designation applies to this contract award. The delivery order represents a continuation of USU's multi-year commitment to NIAID's mission of developing and validating preclinical models essential for evaluating medical countermeasures against emerging and priority infectious disease threats.
Quick answers
Who was awarded contract 75N93022F00002?
75N93022F00002 was awarded to Utah State University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 18, 2022.
How much is contract 75N93022F00002 worth?
The government has obligated $1,002,255 on 75N93022F00002. Its potential value, with all options, is $1,530,720.
Is contract 75N93022F00002 an order under another contract?
Yes. 75N93022F00002 is a delivery order under HHSN272201700041I, an indefinite delivery contract, on NIAID Preclinical Models of Infectious Diseases 2017-2024.
Was contract 75N93022F00002 competed?
The extent of competition for 75N93022F00002 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award